EMA issues advice on use of regdanvimab for treating COVID-19

Following a review of the data, the European Medicines Agency has concluded that regdanvimab is appropriate for the treatment of confirmed COVID-19 in adult patients who do not require supplemental oxygen therapy and are at high risk of progressing to severe COVID-19.

SPS commentary:

The intention is that these recommendations can be used to support national advice on the possible use of this monoclonal antibody before a marketing authorisation is issued.


European Medicines Agency